Study indicates that advances in precision medicine have improved breast cancer treatment
A new study examines how one early example of precision medicine–tumor genome testing–is being used in women with breast cancer to reduce overtreatment and maximize the benefits of chemotherapy. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study found that physician recommendations and final treatment decisions correlated highly with test results, suggesting genome testing helped physicians identify which patients could most benefit from chemotherapy, and those for whom chemotherapy could be safely omitted. Additionally, these personalized recommendations appeared to eliminate racial/ethnic and educational disparities in testing or treatment; however, many women who were tested inaccurately recalled their test results.
Most precision medicine studies in cancer have been confined to patients enrolled in clinical trials. Few have examined how physicians in everyday practice use biomarker tests to recommend chemotherapy or have assessed patient experiences with testing and decision-making. To investigate, Christopher Friese, PhD, RN, of the University of Michigan School of Nursing in Ann Arbor, and his colleagues surveyed 3880 women who were treated for breast cancer in 2013 and 2014 in Los Angeles County, CA or the state of Georgia.
A total of 1527 patients with early stage breast cancer responded to the survey, and 778 had received the 21-gene recurrence score assay (RS), which estimates the risk of disease recurrence and the estimated benefit of chemotherapy in estrogen receptor-positive breast cancer. Overall, 47.2% of patients with RS scores received a recommendation against chemotherapy and 40.6% received a recommendation for it. RS results correlated with recommendations: nearly all patients with high scores received a chemotherapy recommendation, whereas the majority of patients with low-risk results received a recommendation against it. Also, most patients with high RS received chemotherapy, whereas few patients with low scores received it. There were no substantial racial/ethnic differences in testing and treatment. Also, women were largely satisfied with RS and chemotherapy decisions.
"We found that most doctors were using tumor genomic tests in ways that were recommended by professional guidelines, although we found that some patients were having the test where there is no professional recommendation for the test," said Dr. Friese. "For example, about 13 percent of women whose lymph nodes were positive for breast cancer had tumor genomic testing, even though currently it is still under study whether women with positive lymph nodes will benefit from testing and resulting recommendations."
Dr. Friese also noted that although most women were highly satisfied with their experience, only 60 percent of tested women accurately recalled their test results. "This suggests that while precision medicine for breast cancer has left the station, we have also left some women behind. The oncology community needs to do a better job explaining to women the purpose of these tests, how to interpret the results, and what the results mean for their breast cancer treatment."
Full Citation: "Chemotherapy Decisions and Patient Experience with the Recurrence Score Assay for Early-Stage Breast Cancer." Christopher R. Friese, Yun Li, Irina Bondarenko, Timothy Hofer, Kevin C. Ward, Ann S. Hamilton, Dennis Deapen, Allison W. Kurian, and Steven J. Katz. CANCER; Published Online: October 24, 2016 (DOI: 10.1002/cncr.30324).
URL Upon Publication: http://doi.wiley.com/10.1002/cncr.30324.
Author Contact: Jaime Meyers, of the University of Michigan School of Nursing's Communications and Marketing Office, at [email protected] or +1 (734) 764-7006; or Nicole Fawcett, Manager of Cancer Communications at the University of Michigan Comprehensive Cancer Center, at [email protected] or +1 (734) 764-2220.
About the Journal
CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer. CANCER is published on behalf of the American Cancer Society by Wiley and can be accessed online at http://wileyonlinelibrary.com/journal/cancer. Follow us on Twitter @JournalCancer and Facebook https://www.facebook.com/ACSJournals
Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.